Karimi Jirandehi Ashkan, Asgari Reza, Keshavarz Shahbaz Sanaz, Rezaei Nima
Student Research Committee, School of Medicine, Qazvin University of Medical Sciences Qazvin Iran.
USERN Office, Qazvin University of Medical Science Qazvin Iran.
Nanoscale Adv. 2024 Oct 18;6(23):5748-72. doi: 10.1039/d4na00808a.
Statins, traditionally used for managing hyperlipidemia and cardiovascular diseases, have garnered significant interest for their potential anti-cancer properties. Research indicates that statins can inhibit critical processes in cancer development, such as apoptosis, angiogenesis, and metastasis. Despite their promising anti-cancer effects, the clinical application of statins in oncology has been hampered by their inherent low solubility and bioavailability. These pharmacokinetic challenges can be effectively addressed through the use of nano-based drug delivery systems. Nano-formulations enhance the delivery and therapeutic efficacy of statins by improving their solubility, stability, and targeting ability, thus maximizing their concentration within the tumor microenvironment and minimizing systemic side effects. This review delves into the potential of nanoparticles as carriers for statins in cancer therapy. It explores the mechanisms by which statins exert their anti-cancer effects, such as through the inhibition of the mevalonate pathway, modulation of immune responses, and induction of apoptosis. Furthermore, the review examines the development of various statin-loaded nano-formulations, highlighting their advantages over conventional formulations. The novelty of this review lies in its focus on recent advancements in nanoformulations that enhance statin delivery to the tumor microenvironment. By discussing the current advancements and prospects of statin nano-formulations, this review aims to provide a comprehensive understanding of how these innovative strategies can improve cancer treatment outcomes and enhance the quality of life for patients. The integration of nanotechnology with statin therapy offers a novel approach to overcoming existing therapeutic limitations and paving the way for more effective and safer cancer treatments.
他汀类药物传统上用于治疗高脂血症和心血管疾病，因其潜在的抗癌特性而备受关注。研究表明，他汀类药物可以抑制癌症发展中的关键过程，如细胞凋亡、血管生成和转移。尽管他汀类药物具有有前景的抗癌作用，但其在肿瘤学中的临床应用受到其固有的低溶解度和生物利用度的阻碍。通过使用基于纳米的药物递送系统可以有效解决这些药代动力学挑战。纳米制剂通过提高他汀类药物的溶解度、稳定性和靶向能力来增强其递送和治疗效果，从而使肿瘤微环境中的药物浓度最大化，并将全身副作用降至最低。这篇综述深入探讨了纳米颗粒作为他汀类药物在癌症治疗中载体的潜力。它探讨了他汀类药物发挥抗癌作用的机制，如通过抑制甲羟戊酸途径、调节免疫反应和诱导细胞凋亡。此外，该综述还研究了各种载他汀纳米制剂的开发，强调了它们相对于传统制剂的优势。这篇综述的新颖之处在于它关注了增强他汀类药物向肿瘤微环境递送的纳米制剂的最新进展。通过讨论他汀类纳米制剂的当前进展和前景，这篇综述旨在全面了解这些创新策略如何改善癌症治疗效果并提高患者的生活质量。纳米技术与他汀类药物治疗的结合提供了一种克服现有治疗局限性的新方法，并为更有效、更安全的癌症治疗铺平了道路。
